Similar articles

• ACP Journal Club. A 15-microg dose of unadjuvanted influenza A (H1N1) 2009 vaccine was immunogenic in healthy adults within 21 days.

  Granwehr B. Granwehr B. Ann Intern Med. 2010 Jan 19;152(2):JC1-9, JC1-8. doi: 10.7326/0003-4819-152-2-201001190-02009. Ann Intern Med. 2010. PMID: 20083824 No abstract available.
• Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.

  Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. Vesikari T, et al. Vaccine. 2012 Feb 8;30(7):1388-96. doi: 10.1016/j.vaccine.2011.12.009. Epub 2011 Dec 20. Vaccine. 2012. PMID: 22192847 Clinical Trial.
• Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.

  Nassim C, Christensen S, Henry D, Holmes S, Hohenboken M, Kanesa-Thasan N. Nassim C, et al. Pediatr Infect Dis J. 2012 Apr;31(4):e59-65. doi: 10.1097/INF.0b013e31824b9545. Pediatr Infect Dis J. 2012. PMID: 22418661 Clinical Trial.
• Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

  Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. Atmar RL, et al. Clin Infect Dis. 2006 Nov 1;43(9):1135-42. doi: 10.1086/508174. Epub 2006 Sep 25. Clin Infect Dis. 2006. PMID: 17029131 Clinical Trial.
• MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.

  Durando P, Icardi G, Ansaldi F. Durando P, et al. Expert Opin Biol Ther. 2010 Apr;10(4):639-51. doi: 10.1517/14712591003724662. Expert Opin Biol Ther. 2010. PMID: 20218923 Review.